Nuvation Bio (NYSE:NUVB) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Posted by George Bondi on Aug 8th, 2026

Nuvation Bio (NYSE:NUVB – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01), Zacks reports. Nuvation Bio had a negative net margin of 88.18% and a negative return on equity of 44.27%. The business had revenue of $31.69 million for the quarter, compared to analysts’ expectations of $27.03 million.

Here are the key takeaways from Nuvation Bio’s conference call:

IBTROZI net revenue rose 25% quarter over quarter to $23.2 million, with approximately 160 new patient starts; 85% were in the first-line setting, up from roughly 30% at launch. Management said IBTROZI is now the ROS1 TKI market leader in first-line and overall new patient starts.
Management highlighted IBTROZI’s reported 90% response rate and 50-month median duration of response in TKI-naive patients, along with low adverse-event discontinuations and no CNS warning on its label. The company believes these characteristics are driving broad adoption across academic, community, and integrated delivery network accounts.
Nuvation expanded safusidenib development across all major IDH1-mutant glioma segments, including a new Phase III study in newly diagnosed low-grade disease and a Phase II study in patients whose disease progresses after vorasidenib. In updated J201 data, the response rate increased to 52%, while the 36-month progression-free survival rate was 79%.
The company ended the quarter with $661 million in cash, cash equivalents, and marketable securities and raised approximately $279 million through low-coupon convertible notes. Management said the financing reduced cash interest expense, strengthened strategic flexibility, and should provide sufficient capital to reach profitability and fund the anticipated safusidenib launch.
Later-line IBTROZI patient additions are slowing as the company has largely worked through the finite pool of pretreated patients, making future growth increasingly dependent on first-line adoption, improved testing, and converting patients who still receive chemotherapy or immunotherapy.

Nuvation Bio Price Performance

NYSE:NUVB traded up $0.49 during trading hours on Friday, hitting $6.61. 5,772,932 shares of the stock traded hands, compared to its average volume of 6,016,506. The company has a quick ratio of 7.24, a current ratio of 7.44 and a debt-to-equity ratio of 0.15. Nuvation Bio has a 1 year low of $2.18 and a 1 year high of $9.75. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -15.01 and a beta of 1.52. The stock has a 50 day moving average price of $5.76 and a 200 day moving average price of $5.24.

Insider Activity

In other news, insider Stacy Markel sold 125,000 shares of the stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $6.03, for a total value of $753,750.00. Following the completion of the sale, the insider directly owned 32,591 shares of the company’s stock, valued at $196,523.73. This represents a 79.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Mashal bought 25,000 shares of the stock in a transaction that occurred on Tuesday, June 9th. The shares were purchased at an average price of $4.73 per share, for a total transaction of $118,250.00. Following the purchase, the director owned 225,000 shares in the company, valued at $1,064,250. This represents a 12.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders sold 235,668 shares of company stock valued at $1,419,495. 30.11% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Nuvation Bio

A number of hedge funds have recently made changes to their positions in NUVB. Millennium Management LLC raised its stake in Nuvation Bio by 52.4% during the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock valued at $6,642,000 after purchasing an additional 1,298,131 shares during the period. Dimensional Fund Advisors LP grew its holdings in Nuvation Bio by 19.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,321,249 shares of the company’s stock valued at $12,276,000 after buying an additional 551,508 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Nuvation Bio by 852.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company’s stock valued at $24,270,000 after buying an additional 2,424,109 shares during the last quarter. Two Sigma Investments LP raised its position in shares of Nuvation Bio by 95.7% during the third quarter. Two Sigma Investments LP now owns 2,377,570 shares of the company’s stock valued at $8,797,000 after buying an additional 1,162,837 shares during the last quarter. Finally, Armistice Capital LLC lifted its holdings in shares of Nuvation Bio by 359.2% in the third quarter. Armistice Capital LLC now owns 2,296,000 shares of the company’s stock worth $8,495,000 after buying an additional 1,796,000 shares in the last quarter. Institutional investors own 61.67% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on NUVB shares. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Nuvation Bio in a research report on Thursday, July 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Friday, July 17th. Zacks Research upgraded shares of Nuvation Bio from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a research report on Wednesday, June 10th. Finally, Royal Bank Of Canada upped their price objective on Nuvation Bio from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Friday. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Nuvation Bio has an average rating of “Moderate Buy” and a consensus price target of $13.00.

View Our Latest Report on Nuvation Bio

About Nuvation Bio

(Get Free Report)

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.

Earnings History for Nuvation Bio (NYSE:NUVB)

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.